Back

IPSEN – Buy-back programme – Art 5 of MAR – Week 37 – 2023

- 19 September 2023 - 1 mins read

Aggregated presentation by day and by market

Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares * Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 11/09/2023 FR0010259150 154 121.41 CEUX
IPSEN 549300M6SGDPB4Z94P11 11/09/2023 FR0010259150 89 122.50 TQEX
IPSEN 549300M6SGDPB4Z94P11 11/09/2023 FR0010259150 1,357 121.25 XPAR
IPSEN 549300M6SGDPB4Z94P11 12/09/2023 FR0010259150 1,600 126.42 XPAR
IPSEN 549300M6SGDPB4Z94P11 13/09/2023 FR0010259150 43 127.30 AQEU
IPSEN 549300M6SGDPB4Z94P11 13/09/2023 FR0010259150 1,557 126.62 XPAR
IPSEN 549300M6SGDPB4Z94P11 14/09/2023 FR0010259150 74 129.40 AQEU
IPSEN 549300M6SGDPB4Z94P11 14/09/2023 FR0010259150 7 128.90 TQEX
IPSEN 549300M6SGDPB4Z94P11 14/09/2023 FR0010259150 1,419 128.36 XPAR
IPSEN 549300M6SGDPB4Z94P11 15/09/2023 FR0010259150 88 128.60 AQEU
IPSEN 549300M6SGDPB4Z94P11 15/09/2023 FR0010259150 1,512 129.41 XPAR
             
* Two-digit rounding after the decimal   TOTAL 7,900 126.41  

Attachment

Related Press Releases

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
11 July 2024 6 mins read

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
09 July 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
09 July 2024 1 mins read

Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Half-year statement of IPSEN liquidity agreement – 2024 06 30
08 July 2024 1 mins read

Half-year statement of IPSEN liquidity agreement – 2024 06 30
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
02 July 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
02 July 2024 9 mins read

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
25 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
18 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
11 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
10 June 2024 12 mins read

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis